CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Authors
Alessandro Rambaldi
Antonella Russo Rossi
+23 more
Bruno Martino
Claudia Baratè
Diamante Turri
Dino Veneri
Fabio Efficace
Francesco Cottone
Francesco Di Raimondo
Franco Mandelli
Gianantonio Rosti
Giorgio Lambertenghi Deliliers
Giuliana Alimena
Giuseppe Fioritoni
Pietro LEONI
Luciano Levato
Luigia Luciano
Marco Vignetti
Maria Pina Simula
Massimo Breccia
Melissa Dabusti
Micaela Bergamaschi
Michele Baccarani
Siimona Sica
Stefano Ulisciani
Publication date
1 January 2011
Publisher
Abstract
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population Abstract The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations. Submitted April 8, 2011. Accepted June 20, 2011. © 2011 by The American Society of Hematolog
Similar works
Full text
Available Versions
IRIS Università Politecnica delle Marche
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:iris.univpm.it:11566/75154
Last time updated on 11/04/2020